Literature DB >> 11795456

Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS.

M Tintoré1, A Rovira, L Brieva, E Grivé, R Jardí, C Borrás, X Montalban.   

Abstract

AIM OF THE STUDY: To evaluate and compare the capacity of oligoclonal bands (OB) and three sets of MR imaging criteria to predict the conversion of clinically isolated syndromes (CIS) to clinically definite multiple sclerosis (CDMS). PATIENTS AND METHODS: One hundred and twelve patients with CIS were prospectively studied with MR imaging and determination of OB. Based on the clinical follow-up (conversion or not conversion to CDMS), we calculated the sensitivity, specificity accuracy, positive and negative predictive value of the OB, and MR imaging criteria proposed by Paty et al, Fazekas et al and Barkhof et al.
RESULTS: CDMS developed in 26 (23.2%) patients after a mean follow-up of 31 months (range 12-62). OB were positive in 70 (62.5%) patients and were associated with a higher risk of developing CDMS. OB showed a sensitivity of 81%, specificity of 43%, accuracy of 52%, positive predictive value (PPV) of 30% and negative predictive value (NPV) of 88%. Paty and Fazekas criteria showed the same results with a sensitivity of 77%, specificity of 51%, accuracy of 57%, positive predictive value of 32% and negative predictive value of 88%. Barkhof criteria showed a sensitivity of 65%, specificity of 70%, accuracy of 69%, PPV of 40% and NPV of 87%. The greatest accuracy was achieved when patients with positive OB and three or four Barkhof's criteria were selected.
CONCLUSIONS: We observed a high prevalence of OB in CIS. OB and MR imaging (Paty's and Fazekas' criteria) have high sensitivity. Barkhof's criteria have a higher specificity. Both OB and MR imaging criteria have a high negative predictive value.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11795456     DOI: 10.1177/135245850100700603

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  20 in total

1.  Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis.

Authors:  Francesco Sardanelli; Andrea Iozzelli; Caterina Losacco; Alessandra Murialdo; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2003-04       Impact factor: 3.825

2.  Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event.

Authors:  Jean-Christophe Corvol; Daniel Pelletier; Roland G Henry; Stacy J Caillier; Joanne Wang; Derek Pappas; Simona Casazza; Darin T Okuda; Stephen L Hauser; Jorge R Oksenberg; Sergio E Baranzini
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-08       Impact factor: 11.205

Review 3.  Neuroimaging in multiple sclerosis: neurotherapeutic implications.

Authors:  Nancy L Sicotte
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

4.  MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Authors:  Kerstin Bendfeldt; Bernd Taschler; Laura Gaetano; Philip Madoerin; Pascal Kuster; Nicole Mueller-Lenke; Michael Amann; Hugo Vrenken; Viktor Wottschel; Frederik Barkhof; Stefan Borgwardt; Stefan Klöppel; Eva-Maria Wicklein; Ludwig Kappos; Gilles Edan; Mark S Freedman; Xavier Montalbán; Hans-Peter Hartung; Christoph Pohl; Rupert Sandbrink; Till Sprenger; Ernst-Wilhelm Radue; Jens Wuerfel; Thomas E Nichols
Journal:  Brain Imaging Behav       Date:  2019-10       Impact factor: 3.978

Review 5.  Multiple sclerosis and sexual dysfunction.

Authors:  Zhen-Ni Guo; Si-Yuan He; Hong-Liang Zhang; Jiang Wu; Yi Yang
Journal:  Asian J Androl       Date:  2012-03-26       Impact factor: 3.285

Review 6.  [Radiologically isolated syndrome: multiple sclerosis based solely on MRI findings?].

Authors:  J Sellner; L Schirmer; B Hemmer; M Mühlau
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

Review 7.  [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Authors:  O Aktas; M P Wattjes; M Stangel; H-P Hartung
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

Review 8.  B cells and antibodies in multiple sclerosis pathogenesis and therapy.

Authors:  Markus Krumbholz; Tobias Derfuss; Reinhard Hohlfeld; Edgar Meinl
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

9.  Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b.

Authors:  Chris Polman; Ludwig Kappos; Mark S Freedman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Frederick Barkhof; Krzysztof Selmaj; Bernard M J Uitdehaag; Susanne Dahms; Lars Bauer; Christoph Pohl; Rupert Sandbrink
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 4.849

10.  IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome.

Authors:  Johannes Brettschneider; Hayrettin Tumani; Ulrike Kiechle; Rainer Muche; Gayle Richards; Vera Lehmensiek; Albert C Ludolph; Markus Otto
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.